7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one
Modify Date: 2024-01-20 20:02:52
![7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one Structure](https://image.chemsrc.com/caspic/014/112018-01-6.png)
7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one structure
|
Common Name | 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one | ||
|---|---|---|---|---|
| CAS Number | 112018-01-6 | Molecular Weight | 259.26 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C13H13N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-oneBemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research[1]. |
| Name | 6 (3,4 dihydro 3 oxo 2h 1,4 benzoxazin 7 yl) 2,3,4,5 tetrahydro 5 methyl 3 pyridazinone |
|---|---|
| Synonym | More Synonyms |
| Description | Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C13H13N3O3 |
|---|---|
| Molecular Weight | 259.26 |
| Exact Mass | 259.09600 |
| PSA | 79.79000 |
| LogP | 0.78000 |
| 6-[3,4-dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5-methylpyridazin-3-one |
| bemoradan |
| bemorandan |
| 6-(3,4-dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl)-2,3,4,5-tetrahydro-5-methylpyridazin-3-one |
| RWJ 22867 |